Pharmacoepidemiology and Drug Safety

Papers
(The H4-Index of Pharmacoepidemiology and Drug Safety is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information81
50
Correction to “Effect of tramadol and DOACs with special attention to dabigatran on concomitant use, on the risk of mayor bleeding using BIFAP database in Spain”48
Management of epilepsy in Lebanon: Medication reviews and drug‐related problems44
Validation of diagnosis codes for chorioamnionitis in medical encounter data, 2013–201841
External validity in distributed data networks34
Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research31
International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID‐19 pandemic: A cross‐sectional analysis of 66 countries29
Optimizing therapeutic decision‐making for off‐label medicines use: A scoping review and consensus recommendations for improving practice and research+29
Predicting obesity and smoking using medication data: A machine‐learning approach29
Comparison of drug prescribing before and during the COVID‐19 pandemic: A cross‐national European study28
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark27
Quantitative Benefit–Risk Assessment of Vaccination Against COVID‐19: A Systematic Review26
Data Resource Profile: The Danish National Hospital Medicine Register26
Antibiotics and Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: Analysis of Brazilian Pharmacovigilance Registries25
Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data24
Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second‐Line Treatment of Advanced Non–Small Cell Lung Cancer20
Mixed Impact of Direct Healthcare Professional Communications When Considering Proximal Outcomes and the Targeted Population: A Systematic Review20
Letter to the Editor19
Issue Information19
0.12889003753662